Skip to content

Telemonitoring of pulmonary function in patients with Cystic Fibrosis

Telemonitoring of pulmonary function in patients with Cystic Fibrosis - Tele 1

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31622
Enrollment
28
Registered
2008-02-21
Start date
2008-01-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CF Fibrocystic Disease of Pancreas Mucosis Mucovicidosis Pancreatic Fibrosis

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Age 18 years or older * Male or female * Diagnosis of CF confirmed by sweat-test and/or DNA analysis and/or electrophysiology testing * Stable disease * Signed written informed consent.

Exclusion criteria

Exclusion criteria: *Placing on the High Urgency waiting list for lung transplantation

Design outcomes

Primary

MeasureTime frame
* Number of severe exacerbations; a severe exacerbation is defined as an exacerbation which requires treatment with intravenous antibiotic therapy, at the discretion of the treating lung physician. * Number of moderate exacerbations; a moderate exacerbation is defined as exacerbation which allows treatment with oral antibiotic therapy, at the discretion of the treating lung physician.

Secondary

MeasureTime frame
* Quality of life, assessed with EQ-5D and Cystic Fibrosis Questionnaire (CFQ). * Number and route of oral or intravenous antibiotic treatment * Number of emergency room visits in case of suspicion of pulmonary exacerbation * Compliance/adherence with self-testing spirometry assessed with a compliance survey

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)